

University of Miami/ Jackson Memorial Hospital (Main)

ANTIBIOTIC SUSCEPTIBILITY REPORT August 2013- August 4th 2014 (12 months)

Data include 1st isolate from ED and hospitalized patients (JMH Main Campus)

Organism	No.	Aminoglycosides			Carbapenems		Cephalosporins					Penicillins					Quinolones									
		AN	GM	TOB	ERT	MER	CZ	FEP	CTX	CAZ	CRO	AMX	AMP	AZR	OX	PEN	P/T	CIP	LVX	CLN	LZD	NFT	TE	SXT	VA	
Percent Susceptible																										
Gram-Negative	Acinetobacter baumannii	175	/	61	72		60	/	57		51	/	/	/			51	/	53				58	53		
	Citrobacter freundii	43	98	86	90		98	/	98		70	65					90		85			100	80	70		
	Citrobacter koseri	40	100	100	100		100	93	100		98	100					100		95			92	100	98		
	Enterobacter aerogenes	87	100	99	99		99	/	99	100	73	72					77		98			50	98	97		
	Enterobacter cloacae	125	98	98	95	99	96	/	96	100	75	73			74		83		94			56	89	85		
	Enterobacter cloacae complex	64	100	89	95	100	100	/	98		71	68			70		86		97			55	89	87		
	Enterobacter dissolvens	63	100	95	97	100	100	/	100		68	67			72		65		97			75	90	84		
	Escherichia coli	1394	100	81	90	100	100	69	96		88	82	67	50	100		95		57			97	52	51		
	Haemophilus influenzae	43					100			93		100		89	100		100						100	80		
	Klebsiella oxytoca	47	100	96	98		100	38	100		96	93					92		98			100	94	83		
	Klebsiella pneumoniae	679	97	84	82	100	97	72	94		79	77	100	100	100		87	100	79			70	70	70		
	Morganella morganii	43	100	95	98		100	/	98		93	95					98		84			/	/	67		
	Proteus mirabilis	246	100	93	99	100	100	67	99		99	96			100		100		86			/	/	80		
	Pseudomonas aeruginosa	530	95	92	93		85	/	89		87	/		50			99	/	74			/	/	/		
	Serratia marcescens	75	100	93	92		100	/	97		93	81						/	92			/	46	93		
Stenotrophomonas maltophilia	149									/								94						82		
Gram-Positive	Enterococcus faecalis	394	100	100	100		100		100		/		95			100		/	50		100	100	21		100	
	Enterococcus faecium	33											45										67	35		100
	Enterococcus faecium-VRE	72											/								100	28	7		/	
	Staph aureus MSSA	567		99			100					100	100		100	/				81	100	100	88	96	100	
	Staph aureus MRSA	529		95			/					/	/		/	/		100	0	56	100	100	89	90	100	
	Staphylococcus epidermidis	280		75			35								20	/				47	100	100	82	36	100	
	Staphylococcus haemolyticus	51		81			33								25	/				61		100	53	65	100	
	Staphylococcus hominis subsp.	61		92											44	/				46		100	77	59	100	
	Streptococcus agalactiae	106											100				100		98		100					
Streptococcus pneumoniae	49								100		92						50		98	78	100		76	61	100	

AN	Amikacin
GM	Gentamicin
TOB	Tobramycin
ERT	Ertapenem
MER	Meropenem
CZ	Cefazolin
FEP	Cefepime
CTX	Cefotaxime
CAZ	Ceftazidime
CRO	Ceftriaxone
AMX	Amox/Clavulanate
AMP	Ampicillin
AZR	Aztreonam
OX	Oxacillin
PEN	Penicillin
P/T	Pip/Tazobactam
CIP	Ciprofloxacin
LVX	Levofloxacin
CLN	Clindamycin
LZD	Linezolid
NFT	Nitrofurantoin
TE	Tetracycline
SXT	Trimeth/Sulfa
VA	Vancomycin

/ indicates that the drug is clinically ineffective or < 20% susceptible

Note: Enterobacter, Morganella, and Serratia may develop resistance during prolonged therapy with third generation cephalosporins

Legend: 0-59%, 60-89%, 90-100%